# MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

> **NCT05780463** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 485 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** MP0420
- **DRUG:** Placebo
- **BIOLOGICAL:** Remdesivir

## Key facts

- **NCT ID:** NCT05780463
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2022-02-23
- **Final completion:** 2023-06-08
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2024-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780463, "MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05780463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*